X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs FDC LTD. - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA FDC LTD. GSK PHARMA/
FDC LTD.
 
P/E (TTM) x 66.4 22.2 299.0% View Chart
P/BV x 13.4 5.0 267.6% View Chart
Dividend Yield % 2.2 0.9 227.5%  

Financials

 GSK PHARMA   FDC LTD.
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
FDC LTD.
Mar-14
GSK PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs2,760144 1,923.3%   
Low Rs2,04079 2,582.3%   
Sales per share (Unadj.) Rs339.047.6 712.7%  
Earnings per share (Unadj.) Rs41.47.6 544.3%  
Cash flow per share (Unadj.) Rs45.99.0 509.5%  
Dividends per share (Unadj.) Rs35.002.25 1,555.6%  
Dividend yield (eoy) %1.52.0 72.1%  
Book value per share (Unadj.) Rs242.947.5 511.0%  
Shares outstanding (eoy) m84.70177.83 47.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.12.3 302.7%   
Avg P/E ratio x57.914.6 396.3%  
P/CF ratio (eoy) x52.312.3 423.4%  
Price / Book Value ratio x9.92.3 422.2%  
Dividend payout %84.529.6 285.8%   
Avg Mkt Cap Rs m203,28019,784 1,027.5%   
No. of employees `000NANA-   
Total wages/salary Rs m5,2341,221 428.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m28,7158,459 339.5%  
Other income Rs m545394 138.6%   
Total revenues Rs m29,2608,852 330.5%   
Gross profit Rs m5,0592,070 244.4%  
Depreciation Rs m380249 152.5%   
Interest Rs m231 6.4%   
Profit before tax Rs m5,2222,184 239.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892606 312.4%   
Profit after tax Rs m3,5081,353 259.2%  
Gross profit margin %17.624.5 72.0%  
Effective tax rate %36.227.7 130.6%   
Net profit margin %12.216.0 76.4%  
BALANCE SHEET DATA
Current assets Rs m21,8154,355 500.9%   
Current liabilities Rs m15,9991,792 892.8%   
Net working cap to sales %20.330.3 66.8%  
Current ratio x1.42.4 56.1%  
Inventory Days Days6444 143.1%  
Debtors Days Days1925 75.8%  
Net fixed assets Rs m12,4753,025 412.4%   
Share capital Rs m847179 474.2%   
"Free" reserves Rs m19,7268,243 239.3%   
Net worth Rs m20,5738,453 243.4%   
Long term debt Rs m611 56.1%   
Total assets Rs m39,47510,557 373.9%  
Interest coverage x2,612.071.4 3,657.4%   
Debt to equity ratio x00 23.0%  
Sales to assets ratio x0.70.8 90.8%   
Return on assets %8.913.1 67.8%  
Return on equity %17.116.0 106.5%  
Return on capital %26.223.5 111.7%  
Exports to sales %013.3 0.0%   
Imports to sales %03.3 0.0%   
Exports (fob) Rs mNA1,126 0.0%   
Imports (cif) Rs mNA283 0.0%   
Fx inflow Rs m5641,146 49.2%   
Fx outflow Rs m7,429355 2,090.9%   
Net fx Rs m-6,865791 -868.1%   
CASH FLOW
From Operations Rs m4,7281,485 318.4%  
From Investments Rs m-1,042-620 168.2%  
From Financial Activity Rs m-3,066-753 407.5%  
Net Cashflow Rs m620113 549.4%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.7 217.0%  
FIIs % 23.8 7.5 317.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 19.0 81.1%  
Shareholders   102,036 23,730 430.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY19); Net Profit Up 74.5% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, FDC LTD. has posted a net profit of Rs 511 m (up 74.5% YoY). Sales on the other hand came in at Rs 3 bn (up 16.7% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS